Ninlaro (Ixazomib)

Save 50% on brand name Ninlaro from Europe.

Non-english packaging - English label and English insert included. Plan in advance - allow us 7 days to ship your medicine

Two Manufacturer sites can make Ninlaro from Europe: Takeda Ireland Limited Grange Castle Business Park Nangor Road Dublin 22 D22 XR57 Ireland Takeda GmbH Takeda (Werk Singen) Robert Bosch Straße 8 78224 Singen Germany

Information about Ninlaro (Ixazomib)

Ninlaro is the brand name for ixazomib, an oral proteasome inhibitor used in the treatment of multiple myeloma, a type of blood cancer that affects plasma cells in the bone marrow. Ixazomib works by blocking the proteasomes in cancer cells, which are responsible for degrading proteins that control cell function and death. By inhibiting these proteasomes, ixazomib causes the accumulation of toxic proteins within the cancer cells, leading to their death and thereby slowing down or stopping the progression of multiple myeloma.

Ninlaro is typically used in combination with other medications to enhance its effectiveness in treating multiple myeloma.

Product Highlights

Specifically, it is used in:

• For the treatment of patients with multiple myeloma who have received at least one prior therapy. It is often combined with other agents, such as lenalidomide (Revlimid) and dexamethasone, to improve treatment efficacy.
• Ixazomib is particularly useful for patients whose disease has either relapsed (returned) or is refractory (resistant) to prior treatments.

Key Ingredient

• Ixazomib (Ninlaro)

Key Benefits

• Ninlaro has been shown to significantly improve treatment outcomes in multiple myeloma patients, especially in combination with lenalidomide and dexamethasone.
• As an oral medication, Ninlaro offers convenience for patients who may prefer a non-injectable treatment option.
• Ninlaro has demonstrated effectiveness in patients whose disease has become resistant to or relapsed after other therapies.
• Since it is taken orally, Ninlaro can help reduce the need for frequent hospital visits compared to other intravenous treatments for multiple myeloma.
• Clinical studies have shown that ixazomib improves progression-free survival and may lead to fewer side effects compared to some intravenous proteasome inhibitors.

Direction of Use

• Ninlaro is taken once weekly, typically on the same day each week. The dosage is based on the patient's body surface area and may vary depending on their treatment regimen.
• The usual starting dose is 4 mg once a week, which can be reduced based on tolerance.
• It should be taken on an empty stomach, at least 1 hour before or 2 hours after food.
• Treatment is often given in cycles, where the patient takes the medication for a certain number of weeks followed by a rest period.
• Dose adjustments may be required for patients with impaired renal function.

Safety Concerns

• One of the more common side effects of ixazomib is peripheral neuropathy (nerve damage), which can cause symptoms like tingling, numbness, or pain in the hands and feet.
• Ninlaro can cause a decrease in platelet counts (thrombocytopenia), increasing the risk of bleeding or bruising.
• It may also lead to low white blood cell counts (neutropenia), which can make patients more susceptible to infections.
• Some patients may experience nausea, diarrhea, constipation, or other gastrointestinal side effects.
• Liver enzymes may be elevated, so periodic monitoring of liver function is important during treatment.
• Fatigue and weakness are common side effects, which may impact daily activities.
• Patients should be closely monitored for these side effects throughout the course of treatment.

Avoid Ninlaro (Ixazomib) If

• Avoid Ninlaro if you have a known hypersensitivity or allergy to ixazomib or any of its ingredients.
• Ixazomib is metabolized in the liver, and its use may need to be avoided or carefully monitored in patients with severe liver impairment or dysfunction.